CYP3A4 and Anxiety: In contrast, NMVr was associated with a higher likelihood of neuropsychiatric ADRs, such as anxiety and sleep disturbances, in alignment with pharmacokinetic data suggesting that ritonavir’s CYP3A4 inhibition may exacerbate CNS effects by increasing drug exposure and altering neurotransmitter metabolism [55].